SBIR-STTR Reauthorized through 2031
Overview
“Driven by innovative startups, the United States leads the world in scientific breakthroughs and transformative technology – and thanks to this law, SBIR and STTR will continue to power entrepreneurs who are building the industrial base of the future,” said Administrator Kelly Loeffler. “For decades, these cross-agency programs have enabled small, innovative businesses to take bold ideas to commercialization, bolster our national security, and ensure America leads the world in defense, energy, agriculture, biotechnology, space exploration, and other critical industries.” S. 3971 reauthorizes SBIR and STTR programs through September 30, 2031, and includes key reforms that strengthen program integrity.
The Big Picture
NewYorkBIO statement
“On behalf of New York’s life science community, NewYorkBIO thanks House and Senate leaders for championing this bipartisan effort. We are especially grateful to Nydia M. Velázquez, Ranking Member of the House Small Business Committee, for her steadfast leadership throughout the reauthorization process. With reauthorization now secured, NewYorkBIO looks forward to working closely with our member companies, the National Institutes of Health (NIH), and other key partners to ensure that grants are advanced efficiently, fueling the next generation of treatments, cures, and technologies that will improve patient outcomes and drive continued innovation.”
